P. Skolnick, PhD - Depression is a highly heterogenous disorder. Currently available therapy is not sufficiently effective. DOV Pharmaceuticals has triple (serotonin, norepinephrine, dopamine) uptake inhibitors in clinical evaluation. They are expected to be effective in a larger proportion of patients and have more rapid onset of action. They also reduce body weight and plasma triglycerides.